CAR-T cell therapy represents a major breakthrough in the treatment of hematological malignancies, including multiple myeloma, non-Hodgkin lymphoma (NHL), and acute lymphoblastic leukemia (ALL). However, there are several toxicities associated with these agents, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections.
In this podcast, you will hear from experts Eleni Gavriilaki, MD, PhD, G. Papanikolaou Hospital, Thessaloniki, Greece, Kevin McNerney, MD, MSc, Johns Hopkins All Children’s Hospital, St. Petersburg, FL, and Andriyana Bankova, MD, University Hospital Zurich, Zurich, Switzerland, who share some insights into the treatment and management of these common toxicities.
CAR-T therapy in myeloma and lymphoma
CAR-T therapy in AML: challenges and future outlooks
The current state of CAR-T therapy in lymphoma
Myeloma treatment updates from EHA 2022
Updates in classification and risk stratification in MDS
Myeloma 2022: day one highlights
Immune dysregulation and targeting in MDS
The future of CAR-T therapy in ALL
An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs
Key updates in the treatment and management of MPNs
Addressing unmet needs and future treatment approaches in AL amyloidosis
Myeloma treatment in the UK: updates from Muk Nine b: OPTIMUM & the importance of genomics
Updates in lymphoma and CLL treatment in the UK
The importance of early intervention and interception in myeloma
Impact of the COVID-19 pandemic on the EBMT & projects in the pipeline
CAR-T and lymphoma treatment in the UK
Harnessing the power of immunotherapy in myeloma and amyloidosis
The impact of AI and machine learning algorithms in MDS
MMRF-CoMMpass: the genomic basis of myeloma subtypes
Genomics in the age of immuno-oncology
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive